CIK 0001682852
- Large accelerated filer
Moderna, Inc.
Sign in to watch- Ticker
- MRNA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813467528
- Phone
- +1 617-714-6500
- Business address
- 325 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- Moderna Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $50,775,837
- in 5 filings, $50.8M under 10b5-1 plans
Net −$50,775,837. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-07 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −35,872 | $125.73 | $4.5M | 5,416,074 |
| 2023-06-07 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −4,128 | $126.51 | $522K | 5,411,946 |
| 2023-06-07 | Bancel Stephane Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −40,000 | 227,155 | ||
| 2023-06-07 | Klinger Shannon Thyme Chief Legal Officer | Exercise or conversion 10b5-1 | +1,139 | 7,081 | ||
| 2023-06-07 | Klinger Shannon Thyme Chief Legal Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −1,139 | 9,109 | ||
| 2023-06-07 | AFEYAN NOUBAR Director | Sale 10b5-1 | −12,298 | $125.76 | $1.5M | 2,159,911 |
| 2023-06-07 | AFEYAN NOUBAR Director | Sale 10b5-1 | −2,702 | $126.59 | $342K | 2,157,209 |
| 2023-06-06 | Garay Arpa Chief Commercial Officer | Sale 10b5-1 | −2,290 | $125.75 | $288K | 2,547 |
| 2023-06-05 | Garay Arpa Chief Commercial Officer | Exercise or conversion 10b5-1 | +4,562 | 4,837 | ||
| 2023-06-05 | Garay Arpa Chief Commercial Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −4,562 | 13,686 | ||
| 2023-06-02 | Klinger Shannon Thyme Chief Legal Officer | Sale 10b5-1 | −110 | $130.32 | $14K | 5,942 |
| 2023-06-02 | Hoge Stephen President | Sale 10b5-1 | −309 | $130.32 | $40K | 1,632,303 |
| 2023-06-01 | Klinger Shannon Thyme Chief Legal Officer | Exercise or conversion 10b5-1 | +232 | 6,052 | ||
| 2023-06-01 | Klinger Shannon Thyme Chief Legal Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −232 | 2,559 | ||
| 2023-06-01 | Hoge Stephen President | Exercise or conversion 10b5-1 | +651 | 1,632,612 | ||
| 2023-06-01 | Hoge Stephen President | Exercise or conversion · Restricted Stock Units 10b5-1 | −651 | 7,168 | ||
| 2023-06-01 | Bancel Stephane Chief Executive Officer | Exercise or conversion 10b5-1 | +40,000 | $0.99 | $40K | 5,451,946 |
| 2023-06-01 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −1,410 | $125.96 | $178K | 5,450,536 |
| 2023-06-01 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −8,611 | $127.53 | $1.1M | 5,441,925 |
| 2023-06-01 | Bancel Stephane Chief Executive Officer | Sale 10b5-1 | −29,979 | $128.18 | $3.8M | 5,411,946 |
Page 44 of 66 · 1,314 trades